Results 11 to 20 of about 53,238 (282)
Histone deacetylase 2-mediated deacetylation of the Ribonuclease 1 promoter in inflamed human endothelial cells [PDF]
, 2020 Endothelial cells (ECs) function as protective barrier to separate the blood from the surrounding tissue by conducting crucial roles in regulation and maintenance of vascular homeostasis, such as control of vessel permeability or coagulation.
Bedenbender, Katrin
core +1 more source
Macrocyclic Histone Deacetylase Inhibitors [PDF]
Current Topics in Medicinal Chemistry, 2010 Histone deacetylase inhibitors (HDACi) are an emerging class of novel anti-cancer drugs that cause growth arrest, differentiation, and apoptosis of tumor cells. In addition, they have shown promise as anti-parasitic, anti-neurodegenerative, anti-rheumatologic and immunosuppressant agents. To date, several structurally distinct small molecule HDACi have
Sandra C, Mwakwari +3 more
openaire +2 more sources
Histone Deacetylases as Epigenetic Targets for Treating Parkinson’s Disease
Brain Sciences, 2022 Parkinson’s disease (PD) is a chronic progressive neurodegenerative disease that is increasingly becoming a global threat to the health and life of the elderly worldwide.
Yan Li +7 more
doaj +1 more source
Non-Hydroxamate Histone Deacetylase Inhibitors [PDF]
Current Medicinal Chemistry, 2005 A number of histone deacetylase (HDAC) inhibitors have been developed as anticancer agents and most of them are hydroxamic acid derivatives, typified by suberoylanilide hydroxamic acid (SAHA), Trichostatin A (TSA) and NVP-LAQ824. However, hydroxamic acids have been associated with poor pharmacokinetics and severe toxicity. In addition, although isozyme-
Takayoshi, Suzuki, Naoki, Miyata
openaire +2 more sources
Histone deacetylase inhibitors
Clinical Journal of Oncology Nursing, 2013 Histone deacetylase inhibitors (HDAC-Is) are agents that have demonstrated anticancer activity in vivo and in vitro, leading to clinical trials evaluating their efficacy in multiple cancer types. Only two HDAC-Is are currently approved by the U.S.
Claudia E. Rübe +71 more
+5 more sources
Nature Communications, 2021 Current histone microarrays cannot be used to directly study the transient interactions of histone deacetylases (HDACs). Here, the authors show that hydroxamic acid-modified microarrays can capture HDACs, provide insights into their substrate specificity,
Carlos Moreno-Yruela +5 more
doaj +1 more source
Asian Pacific Journal of Cancer Biology, 2020 Objective: DNA methylation, the covalent addition of a methyl group to cytosine, and histone modification play an important role in the establishment and maintenance of the program of gene expression.
Masumeh Sanaei, Fraidoon Kavoosi
doaj +1 more source
Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer [PDF]
, 2016 Introduction: In developed countries, ovarian cancer is the fourth most common cancer in women. Due to the nonspecific symptomatology associated with the disease many patients with ovarian cancer are diagnosed late, which leads to significantly poorer ...
A Hayashi +130 more
core +1 more source
Medicinal chemistry of histone deacetylase inhibitors [PDF]
Arhiv za farmaciju, 2021 Today, we are witnessing an explosion of scientific concepts in cancer chemotherapy. It has been considered for a long time that genetic instability in cancer should be treated with drugs that directly damage the DNA. Understanding the molecular basis of
Ružić Dušan +3 more
doaj +1 more source
Isoform-selective histone deacetylase inhibitors [PDF]
Chemical Society Reviews, 2008 Histone deacetylase (HDAC) proteins are transcription regulators linked to cancer. As a result, multiple small molecule HDAC inhibitors are in various phases of clinical trials as anti-cancer drugs. The majority of HDAC inhibitors non-selectively influence the activities of eleven human HDAC isoforms, which are divided into distinct classes.
Anton V, Bieliauskas, Mary Kay H, Pflum
openaire +4 more sources